Will Neo-Adjuvant Therapies Replace Surgery plus Adjuvant Treatment for Resectable NSCLC?

Phase 1b data also show encouraging preliminary intracranial activity with zongertinib among patients with HER2-mutant non–small cell lung cancer.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Amivantamab/lazertinib also reduces the risk of second progression or death compared with osimertinib in the phase 3 MARIPOSA trial.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Data from the phase 2 PHAROS trial support the European Commission’s approval of encorafenib/binimetinib in NSCLC harboring a BRAF V600E mutation.

Favorable recurrence-free survival and overall survival outcomes were not observed in the overall patient cohort receiving adjuvant chemotherapy for advanced NSCLC.